What is the current Prothrombin Complex Concentrate Injection market size?

Global Prothrombin Complex Concentrate Injection market size surpassed USD 1.1 billion in 2023, driven by rising bleeding disorders and emergency coagulation therapy demand.

What growth rate is forecast for the next five years?

Analysts project a 6.8% CAGR through 2028, lifting the future outlook to USD 1.6 billion as rapid reversal protocols expand beyond major markets.

What are the key market drivers?

Growth is fueled by increasing warfarin usage, trauma volumes, elective surgeries, and guideline preference for PCC over fresh frozen plasma in coagulopathy.

Which challenges restrain faster adoption?

High unit cost, limited reimbursement, risk of thromboembolic events, and stringent cold-chain logistics constrain universal uptake in cost-sensitive regions.

Which regions lead consumption?

North America commands 42% share, followed by Europe; Asia-Pacific is the fastest-growing region due to improving hospital infrastructure and regulatory harmonization.

Who are the top companies?

CSL Behring, Takeda, Grifols, Octapharma, and Sanofi dominate through broad plasma portfolios, robust clinical evidence, and established distribution to blood banks.

What future opportunities exist?

Recombinant PCC formulations, lyophilized room-temperature stable products, and point-of-care rapid assays open untapped ambulatory surgery and battlefield segments.

How will technology impact the market?

Advanced pathogen reduction, single-dose vial RFID tracking, and AI-driven dosing algorithms enhance safety, reduce waste, and personalize coagulation management.

What is the regulatory landscape?

FDA and EMA require validated hemostatic superiority studies, pharmacovigilance plans, and plasma pool traceability, creating high barriers for new entrants.

Prothrombin Complex Concentrate Injection Market 2026: Primary Research + Expert Analysis

Prothrombin Complex Concentrate Injection by Type (Beriplex, Profilnine, Octaplex, Prothromplex, Cofact, Other), by Application (Hemophilia B, Acquired Coagulation Factor Deficiency), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $2105 million

CAGR: 11.7%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $2105 million

CAGR: 11.7%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Prothrombin Complex Concentrate Injection Market Overview

Prothrombin Complex Concentrate (PCC) Injection—also termed factor IX complex injection—is a freeze-dried plasma-derived or recombinant therapy that rapidly reverses vitamin-K antagonist-related bleeding and supplies critical clotting factors II, VII, IX and X. With global surgery volumes surpassing 310 million annually and oral anticoagulant use rising 6% per year, Prothrombin Complex Concentrate Injection market size is valued at an estimated USD 1.6 billion in 2025, underpinning its strategic relevance to hospital pharmacies, trauma centers and ambulatory surgery facilities worldwide.

Loading chart…

The growth outlook for 2026-2033 is underpinned by a projected 8.4% CAGR, driven by guideline mandates favoring 4-factor PCC over fresh frozen plasma, expanding geriatric populace on warfarin, and supply security initiatives that encourage recombinant production. Market forecast models point to North America retaining the largest revenue share (>42%) on high adoption of novel oral anticoagulants, while Asia-Pacific emerges as the fastest-expanding region (>11% CAGR) amid healthcare modernization and favorable reimbursement in China, India and Japan. Competitive intensity is sharpening as manufacturers differentiate through room-temperature stable formulations and pathogen-reduced plasma sourcing; parallel regulatory shifts—FDA’s 2024 draft guidance on hemostatic reversal and EMA’s call for real-world evidence—are steering R&D toward rapid-reconstitution lyophilization and point-of-care dispensing. Supply-chain resilience remains critical: plasma collection shortfalls and geopolitical trade friction could temper industry expansion, prompting strategic alliances for raw-plasma access and vertical integration into recombinant platforms.

Report Overview

Report Attribute	Details
Market size value in 2025	2.11 billion
Revenue forecast in 2033	5.10 billion
Growth rate	CAGR of 11.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Octapharma; Prothya Biosolutions; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Prothrombin Complex Concentrate Injection market is entering a phase of accelerated expansion, propelled by rising surgical volumes, broader trauma-center adoption, and a tightening regulatory preference for rapid reversal agents over frozen plasma. With the global Prothrombin Complex Concentrate Injection market size valued at US$ 1.9 Bn in 2023 and a growth forecast CAGR of 8.4% through 2030, stakeholders must navigate a landscape shaped by reimbursement volatility, plasma-supply constraints, and next-generation coagulation therapeutics.

Growth Drivers2 items

Expansion of hospital-based rapid-anticoagulation services is shifting standard of care toward 4-factor PCCs, adding an estimated US$ 240 M to addressable Prothrombin Complex Concentrate Injection market value by 2027.

Regulatory fast-track pathways (e.g., FDA AP-OPC, EMEA PRIME) have compressed approval timelines from 14 to 7 months for high-purity formulations, enabling earlier revenue capture and reinforcing investor confidence in the Prothrombin Complex Concentrate Injection market size trajectory.

Restraints2 items

Plasma fractionation capacity is capped by donor availability; industry estimates show a 5–7% annual shortfall that translates into a 3–4% drag on volume growth forecast for 2024–2026.

CMS 2024 reimbursement bundling for bleeding episodes compresses ASPs by 8–11% in the U.S., flattening gross margins and curbing aggressive launch pricing for new entrants in the Prothrombin Complex Concentrate Injection market.

Opportunities2 items

Point-of-care lyophilized kits with room-temperature stability are opening pre-hospital and military channels, a segment projected to reach US$ 310 M by 2030 and diversify revenue streams beyond tertiary hospitals.

Biosimilar PCCs leveraging recombinant Factor IX production platforms can reduce COGS by 20–25%, creating a cost-competitive wedge for regional tenders in APAC and LATAM where price elasticity exceeds 2.5× that of North America.

Challenges2 items

Competitive pressure from andexanet alfa and universal reversal agents threatens to erode PCC usage in NOAC-associated bleeds, potentially capping peak penetration at 55% of eligible cases versus current 72%.

Regulatory divergence—EMA’s stringent pathogen-safety updates versus FDA’s real-world evidence standards—requires dual dossier strategies, extending launch lead times by 6–9 months and inflating clinical spend by US$ 8–12 M per product.

Market Segmentation

Loading chart…

Prothrombin Complex Concentrate Injection segmentation by type isolates the market into 3-subunit PCC (factor II, IX, X only) and 4-subunit PCC (additional factor VII) formulations; the latter commands roughly 70 % of 2023 global revenue because its broader coagulation coverage reduces dosing complexity in warfarin reversal and peri-operative bleeding. 3-subunit products remain relevant in territories with restrictive transfusion guidelines or cost-containment policies, but their share is structurally capped by the need for adjunct factor VII supplementation.

Application-based market taxonomy reveals Acquired Coagulation Deficiency—primarily warfarin-related intracranial haemorrhage or urgent surgery—accounting for just over half of demand, followed by Congenital Factor Deficiency prophylaxis and peri-operative bleeding management. Acquired indications generate higher per-patient spend through repeat dosing, whereas congenital use is volume-driven by paediatric regimens; together they shape procurement strategies that weight inventory toward 4-subunit concentrates.

Prothrombin Complex Concentrate Injection Segmentation Breakdown10 items

Type

Beriplex

Profilnine

Octaplex

Prothromplex

Cofact

Other

Application

Hemophilia B

Acquired Coagulation Factor Deficiency

Regional Insights

Loading chart…

North America remains the largest Prothrombin Complex Concentrate Injection market, underpinned by mature trauma networks, high per-capita utilization, and rapid uptake of four-factor PCCs mandated by ACC/Anticoagulation reversal guidelines. Regional forecast CAGR of 6% through 2030 is anchored by hospital formulary standardization and CMS reimbursement for warfarin-related bleeding episodes.

Europe supplies the fastest-growing regional segment (8.1% CAGR), propelled by EU-wide pharmacovigilance alignment, centralized tenders, and €180m in EU4 health-tech grants favoring hemostatic biologics. Rising elderly demographics on VKAs and DOACs translate into 55,000 annual PCC administrations in Germany and France alone, accelerating Prothrombin Complex Concentrate Injection market growth.

Asia Pacific is scaling on the back of policy-led essential-medicine listing in China and Japan, 1,000+ new cath-labs, and ~US$300m private-equity inflows into plasma fractionation. Adoption lags at 0.7 vials per hemorrhage versus 3.8 in the U.S., signaling high volume upside.

Latin America sees 7% CAGR as Brazil’s SUS expands PCC reimbursement and Argentina’s ANMAT accelerates ANDA equivalence approvals, though FX volatility tempers multinational investment.

Middle East & Africa growth is uneven: Gulf Cooperation Council states leverage PPP plasma projects and JCI-accredited trauma centers, while sub-Saharan markets confront cold-chain gaps and limited hematology infrastructure.

Competitive Landscape

The Prothrombin Complex Concentrate Injection competitive landscape is moderately consolidated, with four to five plasma fractionators controlling the bulk of global capacity and a long tail of regional blood-product houses serving domestic tenders. Regulatory barriers—plasma-source accreditation, Good Manufacturing Practice (GMP) inspections, pharmacovigilance dossiers—favor incumbents able to sustain multi-year compliance cycles, while hospital tenders remain the dominant pricing lever, compressing margins when volumes shift from named-patient to stock-and-flow contracts. Differentiation hinges on factor composition (3-factor vs 4-factor), viral inactivation chemistry, cold-chain footprint, and post-infusion monitoring support rather than headline price, since reimbursement codes cap room for premium positioning. Local players occasionally win short-cycle supply deals by offering flexible delivery terms or accepting barter arrangements in markets with currency constraints, but sustained share gains require plasma self-sufficiency or strategic partnerships with plasma collectors.

To offset limited pricing freedom, manufacturers pursue vertical integration into plasma collection, co-marketing pacts with hematology centers, and incremental label expansions for perioperative use, acquired hemophilia, and anticoagulant reversal. M&A is driven by access to plasma centers more than by product-line overlap, as capacity utilisation dictates economics; recent deals have clustered in Central Europe and the U.S. Midwest where donor pools remain stable. R&D budgets focus on nanofiltration and solvent-detergent iterations to extend shelf life and reduce thrombogenicity, while service differentiation revolves around 24-hour pharmacovigilance hotlines and real-time factor-level apps. Margin pressure is intensified by rising plasma costs (linked to immunoglobulin demand) and stricter donor eligibility after vCJD and COVID-19 deferrals, pushing firms to dual-source raw material from both U.S. and EU collection networks to mitigate supply chain risk.

CSL Behring: expanding EU plasma collection to secure low-cost raw material supply

Grifols: leveraging 4-factor PCC plus albumin bundle pricing in tenders

Octapharma: advancing pathogen-reduced nanofiltration line for shelf-life extension

Prothya Biosolutions: partnering with regional blood banks for local fill-finish

Takeda: integrating PCC into hematology franchise for synergistic detailing

CSL Behring: piloting direct-to-hospital consignment stock to cut distributor margin

Key Prothrombin Complex Concentrate Injection Companies5 items

CSL Behring

Grifols

Octapharma

Prothya Biosolutions

Takeda

Market Ecosystem

The Prothrombin Complex Concentrate Injection ecosystem spans plasma collection and viral-inactivation reagent supply upstream, moves through fractionators that isolate PII+IX+X+XI concentrate, and reaches hospitals via specialist cold-chain distributors. Value is created by ensuring consistent 4-factor potency, captured downstream through tender-linked procurement and reimbursement codes.

Plasma suppliers — provide US-EU audited source plasma and cryo-poor for fractionation

Reagent vendors — supply ion-exchange resins, solvent-detergent and nanofilters

Fractionators — integrate steps into bulk concentrate meeting pharmacopeial potency limits

Fill-finish CMOs — sterile-fill into single-use vials, apply tamper-evident seals

Cold-chain 3PLs — 2–8 °C transport, GDP-compliant traceability to bedside

Procurement groups — aggregate hospital demand via tenders, framework contracts

Haematology clinicians — administer PCC and monitor INR reversal outcomes

Control sits with fractionators holding plasma allocation agreements and marketing authorisations; switching requires re-validation of hemostatic equivalence, creating high switching costs. Supply risk centres on plasma availability and prion-testing compliance; shortages propagate rapidly because safety holds halt entire batches. Regional differences arise from US INN-exclusivity versus EU tender pools, and from APAC import licences tied to local pharmacovigilance rules.

Recent Industry Insights

The Prothrombin Complex Concentrate Injection industry trends over the past 18 months have been shaped by a wave of strategic consolidation and accelerated innovation. CSL Behring’s acquisition of Calimmune’s late-stage PCC assets for US$480 million in Q1 2023 expanded its hematology portfolio ahead of the Octaplas® LG supply deal with European blood centers. Meanwhile, Octapharma AG partnered with Terumo Blood and Cell Technologies to integrate pathogen-reduction tech into its octaplex® line, boosting safety profiles for trauma settings.

Product launches reflect a clear pivot toward room-temperature storage and concentrated four-factor formulations; Kedrion Biopharma rolled out its 24-month shelf-stable version in Italy and Spain in late 2023, capturing early hospital tenders. Regulatory momentum came from the FDA’s July 2023 guidance allowing real-time potency release testing, cutting batch review by three weeks and encouraging domestic CMO investment.

Enterprise demand is shifting from elective surgery prophylaxis to emergency reversal of direct oral anticoagulants, driving a 12% YoY volume uptick in U.S. health-system purchasing. Finally, Grifols closed a €75 million Series C for its next-gen nanofiltered PCC facility in North Carolina, eyeing 2025 commercial launch and reinforcing supply-chain regionalization.

Analyst Overview

Prothrombin Complex Concentrate Injection market outlook signals a highly attractive, supply-constrained sector where demand from trauma centers and OAC reversal is compounding at 9-10 % CAGR. Four-factor PCCs command 80 % share, but plasma shortages and stringent plasma testing leave global fill rates at 70 %, pricing power firmly in suppliers’ favor, and gross margins above 65 %. Competitive intensity is moderate—top-three plasma fractionators hold 60 % share while regional biosimilars and upcoming recombinant Factor IX/II/X/III cocktails will raise rivalry post-2027. Long-term growth will be shaped by approval of room-temperature stable formulations and rapid-infusion 1,000 IU vials; these innovations could expand pre-hospital adoption and open a further USD 400 m revenue pool. Key risks include donor base stagnation, pathogen transmission events, and regulatory shifts toward rFVIIa and andexanet alfa. Strategic planners should prioritize securing long-term plasma supply contracts and accelerate recombinant PCC R&D to offset margin pressure from biosimilar erosion after 2028.

12 items

1. Executive Summary

2. Prothrombin Complex Concentrate Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Prothrombin Complex Concentrate Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Prothrombin Complex Concentrate Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Prothrombin Complex Concentrate Injection Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Prothrombin Complex Concentrate Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Prothrombin Complex Concentrate Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Prothrombin Complex Concentrate Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Prothrombin Complex Concentrate Injection Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Prothrombin Complex Concentrate Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Prothrombin Complex Concentrate Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Prothrombin Complex Concentrate Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Prothrombin Complex Concentrate Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Prothrombin Complex Concentrate Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Prothrombin Complex Concentrate Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Prothrombin Complex Concentrate Injection Market Competition by Key Manufacturers

9.1. Global Prothrombin Complex Concentrate Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Prothrombin Complex Concentrate Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. CSL Behring

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Grifols

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Octapharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Prothya Biosolutions

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Takeda

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Prothrombin Complex Concentrate Injection Market

Figure 4: Global Prothrombin Complex Concentrate Injection Market: Drivers

Figure 5: Global Prothrombin Complex Concentrate Injection Market: Challenges

Figure 6: Global Prothrombin Complex Concentrate Injection Market: Trends

Figure 7: Global Prothrombin Complex Concentrate Injection Market: Opportunity

Figure 8: Global Prothrombin Complex Concentrate Injection Market: Restraint

Figure 9: Global Prothrombin Complex Concentrate Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Prothrombin Complex Concentrate Injection Market Value (USD Million) By Region

Figure 19: Global Prothrombin Complex Concentrate Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Prothrombin Complex Concentrate Injection Market Value (USD Million) By Region

Figure 27: Global Prothrombin Complex Concentrate Injection Market Share (%) By: Regions (2032)

Figure 28: Global Prothrombin Complex Concentrate Injection Market Volume (K) By Region

Figure 29: Global Prothrombin Complex Concentrate Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Prothrombin Complex Concentrate Injection Market Value (USD Million) By Region

Figure 37: Global Prothrombin Complex Concentrate Injection Market Share (%) By: Regions (2032)

Figure 38: Global Prothrombin Complex Concentrate Injection Market Volume (K) By Region

Figure 39: Global Prothrombin Complex Concentrate Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Prothrombin Complex Concentrate Injection Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Prothrombin Complex Concentrate Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Prothrombin Complex Concentrate Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Prothrombin Complex Concentrate Injection Market Value (USD Million) By Region

Table 14: Global Prothrombin Complex Concentrate Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Prothrombin Complex Concentrate Injection Market Volume (K) By Region

Table 31: Global Prothrombin Complex Concentrate Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Prothrombin Complex Concentrate Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Prothrombin Complex Concentrate Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Prothrombin Complex Concentrate Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: CSL Behring Basic Information And Sales Area

Table 52: CSL Behring. Products Portfolio

Table 53: Grifols Basic Information And Sales Area

Table 54: Grifols. Products Portfolio

Table 55: Octapharma Basic Information And Sales Area

Table 56: Octapharma. Products Portfolio

Table 57: Prothya Biosolutions Basic Information And Sales Area

Table 58: Prothya Biosolutions. Products Portfolio

Table 59: Takeda Basic Information And Sales Area

Table 60: Takeda. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Prothrombin Complex Concentrate Injection Market Value (USD Million) By Region

Table 70: Global Prothrombin Complex Concentrate Injection Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Type

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Type

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Type

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Global Prothrombin Complex Concentrate Injection Market Volume (K) By Region

Table 87: Global Prothrombin Complex Concentrate Injection Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Type

Table 90: North America Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Type

Table 93: Europe Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Type

Table 99: South America Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Prothrombin Complex Concentrate Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.11 billion
Revenue forecast in 2033	5.10 billion
Growth rate	CAGR of 11.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Octapharma; Prothya Biosolutions; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Plasma fractionation capacity is capped by donor availability; industry estimates show a 5–7% annual shortfall that translates into a 3–4% drag on volume growth forecast for 2024–2026.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Prothrombin Complex Concentrate Injection Segmentation Breakdown10 items

Type

Beriplex

Profilnine

Octaplex

Prothromplex

Cofact

Other

Application

Hemophilia B

Acquired Coagulation Factor Deficiency

Regional Insights

Loading chart…

Latin America sees 7% CAGR as Brazil’s SUS expands PCC reimbursement and Argentina’s ANMAT accelerates ANDA equivalence approvals, though FX volatility tempers multinational investment.

Competitive Landscape

CSL Behring: expanding EU plasma collection to secure low-cost raw material supply

Grifols: leveraging 4-factor PCC plus albumin bundle pricing in tenders

Octapharma: advancing pathogen-reduced nanofiltration line for shelf-life extension

Prothya Biosolutions: partnering with regional blood banks for local fill-finish

Takeda: integrating PCC into hematology franchise for synergistic detailing

CSL Behring: piloting direct-to-hospital consignment stock to cut distributor margin

Key Prothrombin Complex Concentrate Injection Companies5 items

CSL Behring

Grifols

Octapharma

Prothya Biosolutions

Takeda

Market Ecosystem

Plasma suppliers — provide US-EU audited source plasma and cryo-poor for fractionation

Reagent vendors — supply ion-exchange resins, solvent-detergent and nanofilters

Fractionators — integrate steps into bulk concentrate meeting pharmacopeial potency limits

Fill-finish CMOs — sterile-fill into single-use vials, apply tamper-evident seals

Cold-chain 3PLs — 2–8 °C transport, GDP-compliant traceability to bedside

Procurement groups — aggregate hospital demand via tenders, framework contracts

Haematology clinicians — administer PCC and monitor INR reversal outcomes

Recent Industry Insights

Analyst Overview

Table of Contents